The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
by Ishai Menache, Jeevan Pathuri, David Simchi-Levi and Tom Linton Companies face a variety of complex challenges in designing and optimizing their supply chains. Increasing their resilience ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed Inc. - Depositary Receipt () (OTCPK:RSMDF ...
Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...
KYIV, Ukraine—When the director of Russia’s largest film studio met President Vladimir Putin in the Kremlin last month, he made sure to highlight how he had supported the war effort—by ...
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing ...